Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017890476> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2017890476 abstract "The purpose of this study is to identify a positive correlation between serum myeloperoxidase (MPO) and free iron with ovarian cancer stages, such that they may be utilized as biomarkers for early detection of ovarian cancer (OC). Early-stage OC presents with nonspecific symptoms, and most often diagnosis is not made until after the malignancy has spread beyond the ovaries. Mortality rates for this type of malignancy are high due to the lack of an early-stage OC screening method. The rationale of this work stems from our identification of MPO, a hemeprotein previously recognized to be present only in hematopoietic cells, to be present in epithelial OC tissues, while not in normal tissues. Additionally, we have gathered compelling evidence that under oxidative stress, there is destruction of the MPO heme moiety, which results in the elevation of free iron levels in serum.Serum samples were collected from women with early-stage (stages I & II, n=9) and late-stage OC (stages III & IV, n=8), benign gynecologic disorders (n=7), inflammation (endometriosis, n=5), and healthy controls (n=8). We have utilized the MPO ELISA assay and VITROS Fe Slide methods to measure serum MPO and free iron levels, respectively. Data were analyzed with a one-way ANOVA and post-hoc tests. A p<0.05 was considered significant.Both serum MPO and iron are significantly greater in late-stage as compared to early-stage OC (p<0.01). The mean (SD) serum MPO (ng/ml) was 161.0 (33.8) and 98.4(16.3) while mean (SD) serum iron (μg/dl) was 521.3 (110.2) and 289.1(44.70) for the late and early-stage OC, respectively. For serum MPO (ng/ml), both late and early-stage OC were significantly different than healthy control; 43.1 (27.8) and benign gynecologic condition groups; 63.0 (21.0); (p<0.01). The control and benign condition groups were not significantly different.For serum iron (μg/dl), there was a significant difference between early-stage OC; 289.1 (44.70), the healthy control; 104.0 (27.9); the benign gynecologic; 102.1 (32.4); and inflammation groups; 93.1 (18.8). There was no significant difference between healthy control, benign gynecologic, and inflammation groups.There was no significant difference in serum MPO levels between early-stage OC and the inflammation group. However, when examining serum iron levels (μg/dl) in these groups, a significant difference between early-stage OC; 289.1 (44.7) and the inflammation group; 93.1 (18.8) was observed (p<0.01).Collectively, these findings clearly indicate a potential role for the combination of serum MPO and iron as biomarkers for early detection and prognosis of ovarian cancer. In addition, there is a great potential therapeutic value utilizing MPO inhibitors for the treatment of ovarian cancer.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3192. doi:10.1158/1538-7445.AM2011-3192" @default.
- W2017890476 created "2016-06-24" @default.
- W2017890476 creator A5005306051 @default.
- W2017890476 creator A5007987600 @default.
- W2017890476 creator A5036827926 @default.
- W2017890476 creator A5041318626 @default.
- W2017890476 creator A5055897266 @default.
- W2017890476 creator A5069909747 @default.
- W2017890476 creator A5077074927 @default.
- W2017890476 creator A5082980616 @default.
- W2017890476 date "2011-04-15" @default.
- W2017890476 modified "2023-09-26" @default.
- W2017890476 title "Abstract 3192: Positive correlation between serum myeloperoxidase and free iron levels with stage of ovarian cancer: Potential biomarkers for early detection and prognosis of ovarian cancer" @default.
- W2017890476 doi "https://doi.org/10.1158/1538-7445.am2011-3192" @default.
- W2017890476 hasPublicationYear "2011" @default.
- W2017890476 type Work @default.
- W2017890476 sameAs 2017890476 @default.
- W2017890476 citedByCount "0" @default.
- W2017890476 crossrefType "proceedings-article" @default.
- W2017890476 hasAuthorship W2017890476A5005306051 @default.
- W2017890476 hasAuthorship W2017890476A5007987600 @default.
- W2017890476 hasAuthorship W2017890476A5036827926 @default.
- W2017890476 hasAuthorship W2017890476A5041318626 @default.
- W2017890476 hasAuthorship W2017890476A5055897266 @default.
- W2017890476 hasAuthorship W2017890476A5069909747 @default.
- W2017890476 hasAuthorship W2017890476A5077074927 @default.
- W2017890476 hasAuthorship W2017890476A5082980616 @default.
- W2017890476 hasConcept C121608353 @default.
- W2017890476 hasConcept C126322002 @default.
- W2017890476 hasConcept C142724271 @default.
- W2017890476 hasConcept C143998085 @default.
- W2017890476 hasConcept C146357865 @default.
- W2017890476 hasConcept C151730666 @default.
- W2017890476 hasConcept C203565725 @default.
- W2017890476 hasConcept C2776151105 @default.
- W2017890476 hasConcept C2776914184 @default.
- W2017890476 hasConcept C2778248108 @default.
- W2017890476 hasConcept C2779399171 @default.
- W2017890476 hasConcept C2779875672 @default.
- W2017890476 hasConcept C2780427987 @default.
- W2017890476 hasConcept C71924100 @default.
- W2017890476 hasConcept C86803240 @default.
- W2017890476 hasConcept C90924648 @default.
- W2017890476 hasConceptScore W2017890476C121608353 @default.
- W2017890476 hasConceptScore W2017890476C126322002 @default.
- W2017890476 hasConceptScore W2017890476C142724271 @default.
- W2017890476 hasConceptScore W2017890476C143998085 @default.
- W2017890476 hasConceptScore W2017890476C146357865 @default.
- W2017890476 hasConceptScore W2017890476C151730666 @default.
- W2017890476 hasConceptScore W2017890476C203565725 @default.
- W2017890476 hasConceptScore W2017890476C2776151105 @default.
- W2017890476 hasConceptScore W2017890476C2776914184 @default.
- W2017890476 hasConceptScore W2017890476C2778248108 @default.
- W2017890476 hasConceptScore W2017890476C2779399171 @default.
- W2017890476 hasConceptScore W2017890476C2779875672 @default.
- W2017890476 hasConceptScore W2017890476C2780427987 @default.
- W2017890476 hasConceptScore W2017890476C71924100 @default.
- W2017890476 hasConceptScore W2017890476C86803240 @default.
- W2017890476 hasConceptScore W2017890476C90924648 @default.
- W2017890476 hasLocation W20178904761 @default.
- W2017890476 hasOpenAccess W2017890476 @default.
- W2017890476 hasPrimaryLocation W20178904761 @default.
- W2017890476 hasRelatedWork W1508902645 @default.
- W2017890476 hasRelatedWork W15413115 @default.
- W2017890476 hasRelatedWork W1632699915 @default.
- W2017890476 hasRelatedWork W1991421805 @default.
- W2017890476 hasRelatedWork W1992659940 @default.
- W2017890476 hasRelatedWork W2014933087 @default.
- W2017890476 hasRelatedWork W2082537405 @default.
- W2017890476 hasRelatedWork W2353997411 @default.
- W2017890476 hasRelatedWork W2355882681 @default.
- W2017890476 hasRelatedWork W2379084409 @default.
- W2017890476 hasRelatedWork W2393371595 @default.
- W2017890476 hasRelatedWork W2399318953 @default.
- W2017890476 hasRelatedWork W2415762944 @default.
- W2017890476 hasRelatedWork W2419170464 @default.
- W2017890476 hasRelatedWork W2921603664 @default.
- W2017890476 hasRelatedWork W2990541496 @default.
- W2017890476 hasRelatedWork W3024843802 @default.
- W2017890476 hasRelatedWork W3146047024 @default.
- W2017890476 hasRelatedWork W3173520351 @default.
- W2017890476 hasRelatedWork W3031554266 @default.
- W2017890476 isParatext "false" @default.
- W2017890476 isRetracted "false" @default.
- W2017890476 magId "2017890476" @default.
- W2017890476 workType "article" @default.